

Atty. Docket No. PB60227USw

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE: Application of Gordon BRUTON et al.

International Application No.: PCT/EP2004/004245

International Filing Date: April 21, 2004

For: Piperazine Derivates and Their Use for the Treatment of Neurological and Psychiatric Diseases

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

☒ Copies of the references are enclosed

☐ Copies of the references were submitted in parent application Serial No. _____
(37 CFR 1.98(d))

☒ A copy of the International Search Report which issued on International Application No. PCT/EP04/004245 is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 as items 10, 11 and 15 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

A. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

☐ The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).

B. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:

- (1) a final action under § 1.113 or
- (2) a notice of allowance under § 1.311,

whichever occurs first.

Express Mail Label No.: EV332065828USDate of Mailing: 10/17/05

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to "Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on the date shown above.



Patty Wilson

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).
- C. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. [or]
- ☐ Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and
- ☐ The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.
- [X] Please charge any required fees to Deposit Account No.07-1392.
- ☐ A duplicate copy of this paper is attached.

Respectfully Submitted,


Bonnie L. Deppenbrock
Attorney of Record
Registration No. 28,209

Date: 13 October 2005
Customer No. 23347
GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-1577
Facsimile: (919) 483-7988

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	INT'L SERIAL NO.	PCT/EP2004/004245
	INT'L FILING DATE	April 21, 2004
	APPLICANT	BRUTON et al.
	GROUP	
	EXAMINER	
	ATTORNEY DOCKET NO.	PB60227USw

U.S. PATENT DOCUMENTS

Examiner Initials	Serial	Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	1.	5,364,791	11/15/1994	Vegeto et al.			
	2.	5,874,534	2/23/1999	Vegeto et al.			
	3.	5,935,934	8/10/1999	Vegeto et al.			
	4.	6,093,718	7/25/2000	Waterson et al.			
	5.	2002/0115854	8/22/2002	Lam et al.			
	6.	2003/0073718	4/17/2003	Barta et al.			

FOREIGN PATENT DOCUMENTS

Serial	Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
	7.	WO96/10022	4/4/1996	PCT		
	8.	WO97/06802	2/27/1997	PCT		
	9.	WO97/23462	7/3/1997	PCT		
	10.	WO02/32893	4/25/2002	PCT		
	11.	WO02/47679	6/20/2002	PCT		
	12.	WO02/072570	9/19/2002	PCT		
	13.	WO02/076925	10/3/2002	PCT		
	14.	WO03/062234	7/31/2003	PCT		abstract
	15.	WO03/004480	1/16/2003	PCT		
	16.	WO03/024928	3/27/2003	PCT		
	17.	WO03/024929	3/27/2003	PCT		
	18.	WO03/088967	10/30/2003	PCT		
	19.	WO03/103669	12/18/2003	PCT		

Continue on page _____

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

20.	COTTET et al., Trifluoromethyl-Substituted Pyridines Through Displacement of Iodine by in situ Generated (Trifluoromethyl)copper, Eur. J. Org. Chem 327-330 (2002).
21.	COTTET et al., Recommendable Routes to Trifluoromethyl-Substituted Pyridine- and Quinolincarboxylic Acids, Eur. J. Org. Chem 1559-1568 (2003).
22.	GIOVANNINI et al., "Effects of histamine H ₃ receptor agonists and antagonists on cognitive performance and scopolamine-induced amnesia," Behavirural Brain Res. 104:147-155 (1999).
23.	GOODMAN et al., Desymmetrization of Dichloroazaheterocycles, Tetrahedon 55:15067-15070 (1999).
24.	LEURS et al., "Therapeutic potential of histamine H ₃ receptor agonists and antagonists," TiPS 19:177-183 (May 1998).
25.	LOVENBERG et al., "Cloning and Funcnional Expression of the Human Histamine H ₃ Receptor," Molecular Pharmacology 55:1101-1107 (1999).
26.	MICKELSON et al., Asymmetric Synthesis of 2,6-Methylated Piperazines, J. Org. Chem. 60:4177-4183 (1995).
27.	ONODERA and WATANABE, "Histamine H ₃ Antagonists as Potential Therapeutics in the CNS," ed Leurs and Timmerman, pp255-267, Elsevier Science B.V. (1998).
28.	SAKAMOTO et al., Site-Selectivity in the Cyanation of 3-Substituted Pyridine 1 Oxides with Trimethylsilanecarbonitrile, Chem. Pharm. Bull. 33(2):565-571 (1985).
29.	SCHLICKER et al., "Modulation of neurotransmitter release via histamine H ₃ heteroreceptors," Fundam Clin Pharmacol 8:128-137 (1994).

Continue on page _____

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.	